RT Journal Article
SR Electronic
T1 Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 189
OP 204
DO 10.20892/j.issn.2095-3941.2018.0142
VO 16
IS 1
A1 Xuchao Zhang
A1 Zhiyong Liang
A1 Shengyue Wang
A1 Shun Lu
A1 Yong Song
A1 Ying Cheng
A1 Jianming Ying
A1 Weiping Liu
A1 Yingyong Hou
A1 Yangqiu Li
A1 Yi Liu
A1 Jun Hou
A1 Xiufeng Liu
A1 Jianyong Shao
A1 Yanhong Tai
A1 Zheng Wang
A1 Li Fu
A1 Hui Li
A1 Xiaojun Zhou
A1 Hua Bai
A1 Mengzhao Wang
A1 You Lu
A1 Jinji Yang
A1 Wenzhao Zhong
A1 Qing Zhou
A1 Xuening Yang
A1 Jie Wang
A1 Cheng Huang
A1 Xiaoqing Liu
A1 Xiaoyan Zhou
A1 Shirong Zhang
A1 Hongxia Tian
A1 Yu Chen
A1 Ruibao Ren
A1 Ning Liao
A1 Chunyan Wu
A1 Zhongzheng Zhu
A1 Hongming Pan
A1 Yanhong Gu
A1 Liwei Wang
A1 Yunpeng Liu
A1 Suzhan Zhang
A1 Tianshu Liu
A1 Gong Chen
A1 Zhimin Shao
A1 Binghe Xu
A1 Qingyuan Zhang
A1 Ruihua Xu
A1 Lin Shen
A1 Yilong Wu
A1 On behalf of Chinese Society of Clinical Oncology (CSCO) Tumor Biomarker Committee
YR 2019
UL http://www.cancerbiomed.org/content/16/1/189.abstract
AB Next-generation sequencing (NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously. Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology (CSCO) and the China Actionable Genome Consortium (CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians, pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure (SOP), data analysis, report, and NGS platform certification and validation.